Annexon Expected to Report Q1 2025 EPS Loss of $0.30

Summary

Annexon (NASDAQ: ANNX) will release its Q1 2025 financial report on May 12, with analysts predicting a loss of $0.30 per share. In the previous report, they posted a loss of $0.33 per share, missing expectations. Analysts forecast a loss of $1 per share for the current and next fiscal year. The stock opened at $1.97, with a market cap of $216.14 million. Needham & Company maintains a ‘Buy’ rating with a target price of $16. Market Beat

Impact Analysis

1. Business Overview Analysis

• Business Model: Annexon is a biopharmaceutical company focused on developing therapies for severe neuroinflammatory diseases mediated by the classical complement pathway. The core revenue stream is based on advancing its clinical platform targeting these conditions. GlobeNewswire
• Market Position: Annexon operates in a competitive biopharmaceutical industry with a specialized focus on neuroinflammatory disease, offering unique therapies compared to traditional approaches.
• Recent Events: Annexon has granted stock options to employees, indicative of employee incentives and retention strategies. Globe Newswire+ 2

2. Financial Statement Analysis

• Income Statement: Annexon has been reporting losses per share, with current predictions pointing to a continued trend with expected losses of $0.30 per share in Q1 2025, and $1.00 for the fiscal year. This reflects challenges in reaching profitability. Market Beat
• Balance Sheet: The company’s market capitalization stands at approximately $216.14 million, yet it faces ongoing losses, suggestive of potential pressure on asset quality and financial sustainability. Market Beat
• Cash Flow: The specifics on cash flow are not directly provided, but continued losses may imply cash burn that needs monitoring.
• Financial Ratios (inferred from context): The company is likely to have weak profitability ratios given the projected losses. Liquidity and solvency ratios would need close assessment due to the ongoing financial losses.

3. Valuation Assessment

• The current valuation, reflected in the stock price of $1.97, seems undervalued compared to the target price of $16 by Needham & Company, indicating potential upside if Annexon can reverse its loss trends or show progress in clinical trials. Market Beat

Overall, Annexon’s financial position suggests risks due to continued losses, but with potential for growth pending successful clinical outcomes and market expansion. The ‘Buy’ rating hints at optimism regarding future performance. Market Beat